posted on 2025-07-31, 20:45authored byJMG Evers, RA Laskowski, M Bertolli, J Clayton-Smith, C Deshpande, J Eason, F Elmslie, F Flinter, C Gardiner, JA Hurst, H Kingston, U Kini, AK Lampe, D Lim, A Male, S Naik, MJ Parker, S Price, L Robert, A Sarkar, V Straub, G Woods, JM Thornton, DDD Study, CF Wright
Haploinsufficiency in DYRK1A is associated with a recognizable developmental syndrome, though the mechanism of action of pathogenic missense mutations is currently unclear. Here we present 19 de novo mutations in this gene, including five missense mutations, identified by the Deciphering Developmental Disorder study. Protein structural analysis reveals that the missense mutations are either close to the ATP or peptide binding-sites within the kinase domain, or are important for protein stability, suggesting they lead to a loss of the protein's function mechanism. Furthermore, there is some correlation between the magnitude of the change and the severity of the resultant phenotype. A comparison of the distribution of the pathogenic mutations along the length of DYRK1A with that of natural variants, as found in the ExAC database, confirms that mutations in the N-terminal end of the kinase domain are more disruptive of protein function. In particular, pathogenic mutations occur in significantly closer proximity to the ATP and the substrate peptide than the natural variants. Overall, we suggest that de novo dominant mutations in DYRK1A account for nearly 0.5% of severe developmental disorders due to substantially reduced kinase function.
Funding
This work was supported by the Health Innovation Challenge
Fund [grant number HICF-1009-003], a parallel funding partnership
between the Wellcome Trust and the Department of
Health, and the Wellcome Trust Sanger Institute [grant number
WT098051]. The views expressed in this publication are those of
the author(s) and not necessarily those of the Wellcome Trust
or the Department of Health.